A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids)

Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
12/2004
12/23/2004	WO2004111054A1 Pyridinylpyrazolopyrimidinone derivatives as pde 7 inhibitors
12/23/2004	WO2004111037A1 Cyclic tertiary amine compound
12/23/2004	WO2004110995A1 N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors
12/23/2004	WO2004110990A2 Imidazothiazoles and imidazoxazole derivatives as inhibitors of p38
12/23/2004	WO2004110988A1 Protease inhibitors
12/23/2004	WO2004110986A1 Benzamide derivative or salt thereof
12/23/2004	WO2004110489A1 MEDICINAL COMPOSITION FOR PREVENTING OR TREATING Th1 TYPE IMMUNOLOGICAL DISEASE
12/23/2004	WO2004110478A1 Inhibitors of cell migration
12/23/2004	WO2004110477A1 Inhibitors of the leukocyte prommp-9/beta(2) integrin complex
12/23/2004	WO2004110454A1 COMPOSITION FOR TREATMENT FOR OR PREVENTION OF DISEASE NECESSITATING ADMINISTRATION OF ADENOSINE A2a RECEPTOR AGONIST
12/23/2004	WO2004110433A1 Pyrrolidin-1, 2- dicarboxylic acid- 1- [(4- ethinyl- phenyl) - amid]- 2- [(phenyl)- amid] derivative as inhibitors of coagulation factor xa and viia for the treatment of thrombosis
12/23/2004	WO2004110428A1 Anti-inflammatory analgesic adhesive patch
12/23/2004	WO2004110379A2 A1 adenosine receptor antagonists
12/23/2004	WO2004099150A3 3-(1-naphthyl)-2-cyanopropanoic acid derivatives as estrogen receptor ligands
12/23/2004	WO2004085409A3 Compounds and libraries of pyridines, pyrazines, imidazo[1,2-a]pyrazines and 1h-imidazo[4,5-b]pyrazin-2-ones and first and second medical uses thereof
12/23/2004	WO2004084943A8 Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
12/23/2004	WO2004049095A3 Betaine and salicylic acid compositions
12/23/2004	WO2004045563A3 Method of treatment of myocardial infarction
12/23/2004	WO2003037167A3 Pathway of rantes-mediated chemokine synthesis in astrocytes and methods of use therefor
12/23/2004	US20040260268 Drug/drug delivery systems for the prevention and treatment of vascular disease
12/23/2004	US20040260096 Novel substituted 4-phenyl-4-{1h-imidazol-2-yl}-piperidine derivatives and their use as selective non-peptide delta opioid agonists
12/23/2004	US20040260088 Novel compounds
12/23/2004	US20040260069 Modified anti-tnf aplha antibody
12/23/2004	US20040259957 Compounds for treatment of cancer, prodrugs
12/23/2004	US20040259956 Adimistering analgesics by titration for dosage using tramadol and kits
12/23/2004	US20040259952 Formulations for oral administration of cromolyn sodium
12/23/2004	US20040259945 Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
12/23/2004	US20040259930 Linear basic compounds having nk-2 antagonist activity and formulations thereof
12/23/2004	US20040259928 Enzyme inhibitors for antidiabetic agents, antitumor disorders, treatment of skin disorters, anticancer agents and cognitive activators for Alzheimers disease treatment
12/23/2004	US20040259917 Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5
12/23/2004	US20040259908 Integrin VLA-4 ( alpha 4 beta 1) and/or integrin LPAM-1 ( alpha 4 beta 7) antagonists, cell adhesion inhibitor; bioavailability, oral administration;treating inflammatory diseases; e.g. 3-[2-(2,6-dichlorobenzoylamino)pyrid-5-yl]-2-{3-[(2,2-dimethylpropionyl)isobutylamino]-4-methoxyphenyl}propionic acid
12/23/2004	US20040259897 transplant rejection, rheumatoid arthritis, osteoarthritis, diabetes, asthma, inflammatory bowel disease, and chronic obstructive pulmonary disease; inhibitors of Lymphocyte Function-associated Antigen 1 (LFA-1)/intercellular adhesion molecule (ICAM); 2,4-dioxo-1,3,7-triazaspiro[4.4]nonanes
12/23/2004	US20040259890 trans-3'-oxo-N-(trans-4-phenylcyclohexyl)-spiro[cyclohexane-1,1'(3'H)-isobenzofuran]-4-carboxamide e.g.; neuropeptide Y receptor antagonists for treatment of bulimia, obesity or diabetes for example
12/23/2004	US20040259879 Antiarthritic agents; colon cancer, neurodegenerative agents
12/23/2004	US20040259876 Bicyclic compound, production and use thereof
12/23/2004	US20040259875 Incontinence; overactive bladder; neuropathic pain; neuralgia; analgesics; stroke; antiarthritic agents; antiinflammatory agents
12/23/2004	US20040259864 Substituted pyrimidinone derivatives as ligands of integrin receptors
12/23/2004	US20040259863 Type 4 phosphodiesterase inhibitors and uses thereof
12/23/2004	US20040259826 Mitotic kinesin inhibitors
12/23/2004	US20040259821 In nonaqueous solvent; therapy for blood disorders; anticancer agents
12/23/2004	US20040259820 Kit for delivering decitabine in vivo
12/23/2004	US20040259809 Pharmaceutical compositions including an antihistamine and a stimulant and method of use thereof
12/23/2004	US20040259798 Drugs; integrin antagonist; antiinflammatory agents; leukemia therapy
12/23/2004	US20040259787 C1q and collectin receptor
12/23/2004	US20040259781 Drug screening ; polypeptide interfers with binding of fibronectin to; anticancer agents; antihistamines, antiarthritic agents, autoimmune disease, wound healing agents
12/23/2004	US20040259201 Recombinant surfactant protein D compositions and methods of use thereof
12/23/2004	US20040259150 Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
12/23/2004	US20040259110 Gene PRV-1 and its use
12/23/2004	US20040258772 Methods of treating angiogenesis, tumor growth, and metastasis
12/23/2004	US20040258691 Treating psoriasis in a patient by administering a therapeutically effective amount of an antibody immunospecific for vetronectin receptor av beta 3; antiinflammatory agents; antibody does not immunoreact with integrins other than av beta 3; cell adhesion
12/23/2004	US20040258678 Isolated nucleic acid having high identity to sequence 215; vectors, host cells, antibodies
12/23/2004	US20040258647 Active ingredient-containing cosmetic cleansing emulsions
12/23/2004	DE10325049A1 New peptide derivatives containing cell-adhesion molecule and phosphonate-containing anchor component, useful for treating disorders associated with implants, are inhibitors of integrins
12/23/2004	DE10103860B4 Transdermales therapeutisches System für die Verabreichung carboxylgruppenhaltiger, nichtsteroidaler Antiphlogistika, sowie Verfahren zu seiner Herstellung Transdermal therapeutic system for the administration of carboxyl-containing, non-steroidal anti-inflammatory agents, and to processes for its preparation
12/23/2004	CA2756058A1 Fused compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
12/23/2004	CA2528929A1 Cyclic tertiary amine compound
12/23/2004	CA2528883A1 Pharmaceutical compositions for preventing or treating th1-mediated immune diseases
12/23/2004	CA2528367A1 A1 adenosine receptor antagonists
12/23/2004	CA2528186A1 Molecules for targeting and releasing therapeutic compounds, and the use thereof
12/23/2004	CA2527236A1 Thiotungstate analogues and uses thereof
12/23/2004	CA2526387A1 Benzamide derivative or salt thereof
12/23/2004	CA2526285A1 Inhibitors of p38 and methods of using the same
12/22/2004	EP1489187A1 Osteoclast differentiation inhibitors
12/22/2004	EP1489186A1 Angiogenesis inhibitors
12/22/2004	EP1489183A1 Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells
12/22/2004	EP1489090A1 Novel pseudoerythormycin derivatives
12/22/2004	EP1489088A1 Novel alpha-amino-n-(diaminophosphinyl)lactam derivative
12/22/2004	EP1489083A1 Fused bicyclic pyridine derivative as tachykinin receptor antagonist
12/22/2004	EP1489081A1 Spiro derivatives and adhesion molecule inhibitors comprising the same as the active ingredient
12/22/2004	EP1488803A1 Neurotoxic component of botulinum toxins for treating neuromuscular disorders
12/22/2004	EP1488799A2 Soluble lymphotosin-Beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
12/22/2004	EP1488787A1 Topical stabilized formulations containing ketoprofen
12/22/2004	EP1487876A1 The use of an epitope of vascular endothelial growth factor receptor kdr/flk-1
12/22/2004	EP1487865A2 USES OF MAMMALIAN CYTOKINEi; RELATED REAGENTS
12/22/2004	EP1487842A1 An optically acitve pyridine derivative and a medicament containing the same
12/22/2004	EP1487841A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
12/22/2004	EP1487829A1 Thiadiazolylpiperazine derivatives useful for treating or preventing pain
12/22/2004	EP1487828A2 Morpholinyl-urea derivatives for use of the treatment of inflamatory diseases
12/22/2004	EP1487827A1 Anti-inflammatory morpholin-acetamide derivatives
12/22/2004	EP1487824A1 Diamino-pyrimidines and their use as angiogenesis inhibitors
12/22/2004	EP1487823A1 Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidine with cdk inhibitory activity
12/22/2004	EP1487821A1 Benzodiazepine-substituted piperidines for utilization in the treatment of cardiovascular diseases
12/22/2004	EP1487817A1 Piperidine derivatives useful as modulators of chemokine receptor activity
12/22/2004	EP1487811A1 N-sulfonylurea apoptosis promoters
12/22/2004	EP1487807A2 New compounds
12/22/2004	EP1487805A1 Pyrimidine derivatives
12/22/2004	EP1487794A1 Monocyclic aroylpyridinones as antiinflammatory agents
12/22/2004	EP1487793A1 Piperidine derivatives useful as modulators of chemokine receptor activity
12/22/2004	EP1487776A1 Acid and ester compounds and methods of using the same
12/22/2004	EP1487494A2 Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
12/22/2004	EP1487489A2 METHODS OF PREVENTING OR TREATING DISORDERS BY ADMINISTERING AN INTEGRIN avb3 ANTAGONIST IN COMBINATION WITH AN HMG-CoA REDUCTASE INHIBITOR OR A BISPHOSPHONATE
12/22/2004	EP1487480A2 Fusion molecules and methods for treatment of immune diseases
12/22/2004	EP1487471A2 Methods for treating autoimmune disorders and reagents related thereto
12/22/2004	EP1487470A1 Identification of free-b-ring flavonoids as potent cox-2 inhibitors
12/22/2004	EP1487466A1 Use of lactobacillus farciminis for the prevention or pathology of digestive pathologies
12/22/2004	EP1487457A1 Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation
12/22/2004	EP1487456A1 Benzenesulphonate salt of a morpholine urea derivative for use as a ccr-3 antagonist in the treatment of inflammatory conditions
12/22/2004	EP1487455A1 Morpholine derivatives substituted at the 2-position by an arylalkylurea group for use as ccr-3 antagonists in the treatment of inflammatory conditions
12/22/2004	EP1487454A1 Morpholine derivatives substituted at the 2-position by a heterocyclylalkylurea group for use as ccr-3 antagonists in the treatment of inflammatory conditions
12/22/2004	EP1487453A1 N- [(2s)-4-(3,4-difluorobenzyl)morpholin-2-yl]methyl -2- 3-[(methylsulphonyl)amino]phenyl acetamide as ccr3 antagonist for the treatment of inflammatory conditions

1 ... 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 ... 1272